{"id":"NCT03019185","sponsor":"Biogen","briefTitle":"A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL","officialTitle":"A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-03-02","primaryCompletion":"2020-10-06","completion":"2020-10-30","firstPosted":"2017-01-12","resultsPosted":"2023-10-11","lastUpdate":"2025-06-11"},"enrollment":187,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Alport Syndrome"],"interventions":[{"type":"DRUG","name":"Placebo Oral Capsule","otherNames":[]},{"type":"DRUG","name":"Bardoxolone Methyl","otherNames":["RTA 402"]}],"arms":[{"label":"Phase 2 Bardoxolone Methyl","type":"EXPERIMENTAL"},{"label":"Phase 3 Bardoxolone Methyl","type":"ACTIVE_COMPARATOR"},{"label":"Phase 3 Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The Phase 2 portion of the trial will be open-label and enroll up to 30 patients. The Phase 3 portion of the trial will be double-blind, randomized, placebo-controlled and will enroll up to 180 patients.","primaryOutcome":{"measure":"Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 12 Weeks of Treatment (Phase 2)","timeFrame":"Baseline through 12 weeks after participant receives the first dose in the Phase 2 study","effectByArm":[{"arm":"Phase 2 Bardoxolone Methyl","deltaMin":13.37,"sd":1.4111}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":17},"locations":{"siteCount":63,"countries":["United States","Australia","France","Germany","Japan","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["36411058","33789284","33159213"],"seeAlso":["https://www.cardinalclinicaltrial.com/"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":30},"commonTop":["Muscle spasms","Alanine aminotransferase increased","Nasopharyngitis","Headache","Fatigue"]}}